AIM ImmunoTech Inc (AIM) stock surged more than 100% in pre-market trading after a Japanese patent for its Ampligen cancer treatment was fully approved. The patent covers using Ampligen with checkpoint inhibitors for various cancers, including pancreatic. Valid until 2039, the approval followed a six-month opposition period. AIM holds similar patents in the US and Netherlands.